Lorelei Mucci and Philip Kantoff on Outcomes Research and the IRONMAN Project

Lorelei Mucci and Phil Kantoff discuss the outcomes research of International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerland.  Alicia Morgans interviews Lorelei Mucci and Phil Kantoff to discuss the changing treatment landscape for treating prostate cancer and the goal of the IRONMAN study.  

Biographies:
Lorelei Mucci ScD, MPH is an associate professor of epidemiology at the Harvard School of Public Health, and she co-leads the Cancer Epidemiology program at the Dana Farber/Harvard Cancer Center. She has more than 10 years of research and teaching experience in cancer epidemiology, with a focus on prostate cancer. As a primary or co-investigator on several funded studies, she bridges population science and molecular biology to look across the spectrum of prostate cancer incidence, cancer mortality and somatic alterations. The overarching goals of this multidisciplinary research are to reduce mortality and suffering associated with prostate cancer and to improve overall health among men. Her work puts her in collaboration with a renowned group of prostate cancer investigators and clinicians from around the world on a number of groundbreaking studies including the Nordic Twin Study of Cancer (NorTwinCan), the Prostate Cancer Patho-epidemiology Collaboration (PC)2, and Steps for Prostate Cancer Health and Survival (SPaRTACuS), a walking intervention study among men with prostate cancer

Philip Kantoff MD is the Chairman of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College. He is also the incumbent George J. Bosl Chair in Medicine. Dr. Kantoff oversees the clinical care, translational and clinical research of almost 400 faculty members in the Department of Medicine. He ensures the mentorship of fellows and junior faculty and cares for patients with prostate cancer. Dr. Kantoff’s laboratory- based research is devoted principally to the genetics and genetic epidemiology of prostate cancer, resistance to androgen deprivation therapy and the discovery of new biomarkers as potential prognostic and therapeutic targets. He lectures widely on both his research and the care of patients with these malignancies. 

Alicia Morgans, MD

Access to all Advanced Prostate Cancer Consensus Conference Video Coverage 

Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer